New drug Lishimin ® (Lisna peptide injection) New indications have been officially approved by China's State Drug Administration

Sanofi China has announced that a newdrug for the treatment of type 2 diabetes,(http://the Lissin ® (Lisnapeptide Injection), has been officially approved by China's nationaldrug(http://regulatory authorityreceive metformin monosyformin or combined sulfonindrug(http://and/or basic insulin to treat adults with type 2 diabetes with poor blood sugar control on the basis of diet control and exercise, in order to achieve the goal of blood sugar controlabout the of lith®
osensitivity® is a new type of GLP-1 (endogenous intestinal insulin-promoting hormone) receptor agonist, the patient once a day injectionIt is currently the only GLP-1 receptor agonist approved in China for joint base insulin usePreviously, the ® has been approved for the use of metformin monosylene or combined sulfonatin drugs on the basis of diet control and exercise for treatment of adults with type 2 diabetes with poor blood sugar controlclinical studies have shown that the combination of lising ® and basic insulin can improve both fasting blood sugar and post-meal blood sugar® and approved in China is based on a multi-country, multi-center, randomized, double-blind, placebo-controlled clinical Phase III study called GetGoal-L-C The study was based on people with type 2 diabetes in China, accounting for 56% of the study The main endpoint of studies was the decline in glycated hemoglobin from baseline after 24 weeks of treatment Secondary endpoints include a 24-week blood sugar rate (HbA1c 7%), post-meal blood sugar, fasting blood sugar and a decrease in weight from the baseline results confirmed that when receiving basic insulin therapy for poor blood sugar control, the use of a ® can effectively reduce the patient's post-meal blood sugar, significantly reduce the risk of glycation hemoglobin, and have multiple benefits from weight loss At the same time, the ® was well tolerated during 24 weeks of treatment